Bright Minds Biosciences Statistics
Total Valuation
CSE:DRUG has a market cap or net worth of CAD 425.01 million. The enterprise value is 373.76 million.
Market Cap | 425.01M |
Enterprise Value | 373.76M |
Important Dates
The last earnings date was Thursday, August 14, 2025.
Earnings Date | Aug 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
CSE:DRUG has 7.08 million shares outstanding. The number of shares has increased by 49.66% in one year.
Current Share Class | 7.08M |
Shares Outstanding | 7.08M |
Shares Change (YoY) | +49.66% |
Shares Change (QoQ) | +0.65% |
Owned by Insiders (%) | 22.42% |
Owned by Institutions (%) | 43.09% |
Float | 2.98M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | 8.20 |
P/TBV Ratio | 8.20 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -41.91 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 86.56, with a Debt / Equity ratio of 0.00.
Current Ratio | 86.56 |
Quick Ratio | 85.39 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -962.50 |
Financial Efficiency
Return on equity (ROE) is -30.79% and return on invested capital (ROIC) is -18.53%.
Return on Equity (ROE) | -30.79% |
Return on Assets (ROA) | -18.31% |
Return on Invested Capital (ROIC) | -18.53% |
Return on Capital Employed (ROCE) | -16.59% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4,037.93% in the last 52 weeks. The beta is 0.17, so CSE:DRUG's price volatility has been lower than the market average.
Beta (5Y) | 0.17 |
52-Week Price Change | +4,037.93% |
50-Day Moving Average | 40.94 |
200-Day Moving Average | 48.89 |
Relative Strength Index (RSI) | 77.28 |
Average Volume (20 Days) | 1,105 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -8.61M |
Pretax Income | -8.92M |
Net Income | -8.92M |
EBITDA | n/a |
EBIT | -8.61M |
Earnings Per Share (EPS) | -1.44 |
Balance Sheet
The company has 51.39 million in cash and 141,030 in debt, giving a net cash position of 51.25 million or 7.23 per share.
Cash & Cash Equivalents | 51.39M |
Total Debt | 141,030 |
Net Cash | 51.25M |
Net Cash Per Share | 7.23 |
Equity (Book Value) | 51.83M |
Book Value Per Share | 7.32 |
Working Capital | 51.76M |
Cash Flow
Operating Cash Flow | -7.89M |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
CSE:DRUG does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -49.66% |
Shareholder Yield | n/a |
Earnings Yield | -2.10% |
FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on July 14, 2023. It was a reverse split with a ratio of 0.2.
Last Split Date | Jul 14, 2023 |
Split Type | Reverse |
Split Ratio | 0.2 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |